FCGR3A and cancer: Thus, NK cells have widely been considered for treatment of cancer, including in the emerging therapies based on monoclonal antibodies (MAb), since NK cells can recognize antibody-opsonized target cells through CD16 (FcγRIIIa) molecules and eliminate them [29].